Tenax Therapeutics, Inc. (TENX) — Financial statements
Income statement, balance sheet, and cash flow for Tenax Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 33↑157.1% | 13↑293.6% | 3↓40.0% | 5↓78.6% | 25 | |
| General & Administrative Expenses | 24↑249.5% | 7↑35.6% | 5↓11.8% | 6↓25.1% | 8 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↑249.5% | 7↑35.6% | 5↓11.8% | 6↓25.1% | 8 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 56↑189.2% | 19↑136.8% | 8↓25.5% | 11↓66.2% | 33 | |
| Total Costs & Expenses | 56↑189.2% | 19↑136.8% | 8↓25.5% | 11↓66.2% | 33 | |
| Operating Results | ||||||
| Operating Income | -56↓189.2% | -19↓136.8% | -8↑25.5% | -11↑66.2% | -33 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 0.01↓92.9% | 0.11↑4.0% | 0.11 | |
| EBITDA | -56↓220.8% | -18↓128.9% | -8↑29.7% | -11↑66.2% | -32 | |
| EBIT | -56↓220.8% | -18↓128.7% | -8↑30.4% | -11↑66.0% | -32 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↑102.0% | 2↑7990.0% | -0.02↓439.4% | -0.00↓368.2% | -0.00 | |
| Interest Income | 4↑99.5% | 2 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.02↓4.0% | 0.02↑439.4% | 0.00↑368.2% | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -2↓250.1% | -0.55↓5851.5% | -0.01↑96.4% | -0.25 | |
| Other Income / Expenses | 4↑100.1% | 2↑261.8% | 0.52↑10915.2% | 0.00↓98.1% | 0.25 | |
| Income Before Tax | -53↓198.8% | -18↓128.3% | -8↑30.2% | -11↑66.0% | -32 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -53↓198.8% | -18↓128.3% | -8↑30.2% | -11↑66.0% | -32 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -53↓198.8% | -18↓128.3% | -8↑30.2% | -11↑66.0% | -32 | |
| Bottom-Line Net Income | -53↓198.8% | -18↓128.3% | -8↑30.2% | -11↑66.0% | -32 | |
| EPS (Basic) | -1.34↓16.5% | -1.15↑96.3% | -31.09↑94.8% | -600.80↑76.2% | -2,524.80 | |
| EPS (Diluted) | -1.34↓16.5% | -1.15↑96.3% | -31.04↑94.8% | -600.80↑76.2% | -2,524.80 | |
| Weighted Average Shares | 39↑156.8% | 15↑6057.9% | 0.25↑1248.5% | 0.02↑43.0% | 0.01 | |
| Weighted Average Diluted Shares | 39↑156.8% | 15↑6046.9% | 0.25↑1250.9% | 0.02↑43.0% | 0.01 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.